ArticleHypertension research : official journal of the Japanese Society of Hypertension2023
Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an efficacy and safety, proof-of-principle study.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- A systematic review to compare adrenalectomy and mineralocorticoid receptor antagonists in patients with unilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Clinical and Biochemical Outcomes of Super-Selective Adrenal Artery Embolization in Primary Aldosteronism: A Systematic Review and Meta-Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2025Pooled it
- Efficacy, Quality of Life, and Cost-Effectiveness of Superselective Adrenal Arterial Embolization in Idiopathic Hyperaldosteronism: A Comparative Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Article
- Arterial-venous adrenal embolization for aldosterone adenoma: a preliminary exploratory study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Bilateral superselective adrenal artery embolization for primary aldosteronism: A comparative evaluation of clinical efficacy and safety.The Journal of international medical research · 2026Observational
- Biological age acceleration in primary aldosteronism: associations with renin, aldosterone, aldosterone-to-renin ratio, and left ventricular mass index.Journal of hypertension · 2026Article
- Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism.Journal of the American Heart Association · 2026Article
- Beyond Drugs and Surgery: Superselective Adrenal Artery Embolization Redefines Primary Aldosteronism Management-A Systematic Review and Meta-Analysis.International journal of endocrinology · 2026Article
- Review
- Association of Plasma Aldosterone Concentration With Early Renal Injury Biomarkers in Primary Aldosteronism: A Propensity-Matched Comparative Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Superselective Adrenal Artery Embolization as a Novel Alternative Treatment for Aldosterone-Producing Adenomas: A Case of Refractory Hypertension With Concomitant Autonomous Cortisol Secretion.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Review
- Bilateral superselective adrenal artery embolization for bilateral primary aldosteronism: a novel approach in an efficacy and safety proof-of-principle trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Establishment of a scoring model for predicting clinical outcomes in patients with unilateral primary aldosteronism after superselective adrenal artery embolization.Irish journal of medical science · 2024Article
- Rationality and implication of catheter-based adrenal ablation for bilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.BMC surgery · 2024Article
- Comparative Assessment of the Influence of Embolizing Agents on the Adrenal Parenchyma.Bulletin of experimental biology and medicine · 2024Article
- Efficacy and safety of adrenal arterial embolization for primary aldosteronism: a systematic review and meta-analysis.Gland surgery · 2024Article
- The application of superselective adrenal artery embolization in primary aldosteronism: evaluation, challenges, and response to Mr. Cabrelle and his team.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superselective adrenal arterial embolization (SAAE) appears to be beneficial in primary aldosteronism (PA) patients with lateralized aldosterone secretion (unilateral PA). As confirmed by adrenal vein sampling (AVS), nearly 40% of PA patients would be PA without lateralized aldosterone secretion (bilateral PA). We aimed to investigate the efficacy and safety of SAAE on bilateral PA. We identified 171 bilateral PA patients from 503 PA patients who completed AVS. Thirty-eight bilateral PA patients received SAAE, and 31 completed a median 12-month clinical follow-up. The blood pressure and biochemical improvements of these patients were carefully analyzed. 34% of patients were identified as bilateral PA. Plasma aldosterone concentration, plasma renin activity, and aldosterone/renin ratio (ARR) were significantly improved 24-h after SAAE. SAAE was associated with 38.7% and 58.6% of complete/partial clinical and biochemical success within a median 12-month follow-up. A significant reduction in left ventricular hypertrophy was shown in patients who obtained complete biochemical success compared with partial/absent biochemical success. SAAE was associated with a more apparent nighttime blood pressure reduction than daytime blood pressure reduction in patients with complete biochemical success. No major adverse safety events related to SAAE were reported during the intraoperative, postoperative, and follow-up periods. SAAE was associated with blood pressure and biochemical improvements in part of bilateral PA and appeared safe. The biochemistry success was accompanied by improved cardiac remodeling and a more prominent decrease in nocturnal blood pressure. This study was part of a trial registered with the Chinese Clinical Trial Registry, number ChiCTR2100047689.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.